Trent Mason, MD
Family Practice · Glen Dale, WVNPI 1477548212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 29.3% of the total. Reporting peaked in 2020 at $244 and has fallen 93.6% since, to $16 in 2025. Among family practice clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $12.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$266
- GSK$141
- Lilly USA, LLC$137
- Boehringer Ingelheim$74
- Pfizer$69
- AstraZeneca$65
- plus $155 from 6 others
What the payments were for
- Food & beverage$908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $266 |
| GSK | 10 | $141 |
| Lilly USA, LLC | 9 | $137 |
| Boehringer Ingelheim | 4 | $74 |
| Pfizer | 4 | $69 |
| AstraZeneca | 4 | $65 |
| Amgen | 3 | $42 |
| Shield Therapeutics Inc | 2 | $29 |
| Merck | 1 | $27 |
| AbbVie | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Johnson & Johnson | 1 | $12 |
How this compares
$908 in reported general payments places this provider in the 95th percentile of 96 family practice providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $117,329 |
| EliquisApixaban | 112 | $76,016 |
| JanuviaSitagliptin Phosphate | 40 | $38,367 |
| JardianceEmpagliflozin | 52 | $35,785 |
| FarxigaDapagliflozin Propanediol | 59 | $34,345 |
| XareltoRivaroxaban | 38 | $33,303 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $26,633 |
| MounjaroTirzepatide | 24 | $23,867 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,566 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $16,707 |
| RexultiBrexpiprazole | 11 | $15,347 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,428 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $14,101 |
| LinzessLinaclotide | 25 | $13,030 |
| TrulicityDulaglutide | 12 | $11,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $266 | $117,329115 claims |
| PfizerEliquis | $69 | $76,016112 claims |
| MerckJanuvia, Janumet Xr | $27 | $65,00072 claims |
| AstraZenecaFarxiga, Symbicort, Nexium | $65 | $41,14485 claims |
| Boehringer IngelheimJardiance | $74 | $35,78552 claims |
| Lilly USA, LLCMounjaro, Trulicity | $137 | $35,66336 claims |
| Johnson & JohnsonXarelto | $12 | $33,30338 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $141 | $20,14730 claims |
| AbbVieLinzess | $24 | $13,03025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 family practice providers in West Virginia.
Other family practice in Glen Dale
- Sean di CristofaroHurricane$7K
- Nathan HicksClarksburg$671
- Robert PowersHarpers Ferry$368
- Robert WadeMoundsville$260
- Jeremy HensleyMartinsburg$176
- Lauren RutkowskiWheeling$20
- Sidney SissonMorgantown$4
- Shaylee PeckensMorgantown$0
- Leila ElderHarpers Ferry$0
- Keith de YoungSummersville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.